It is a known, though uncommon, risk associated with GLP-1 medications
THE EU FISH MARKET 2021 EDITION (2022)
How These Peptides Work PT-141 and Melanotan II are both synthetic cyclic peptide analogues that act on melanocortin receptors, particularly MC3R and MC4R in the central nervous system [2] [5]
It is administered as a once-weekly subcutaneous injection and is available through the NHS for eligible patients according to NICE guidance
Cunningham helps patients choose
According to the Summary of Product Characteristics (SmPC), these include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (very common) Decreased appetite (very common) Vomiting (common, affecting up to 1 in 10 people) Constipation (common) Abdominal pain (common) Dyspepsia (common) Cholelithiasis (common) Headache (common) These gastrointestinal effects typically occur during the initial weeks of treatment or following dose escalation, and often diminish over time as the body adjusts to the medication